Imigran (Sumatriptan)

Sumatriptan is a selective agonist of the 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. Activation of these receptors causes constriction of dilated intracranial vessels and inhibits the release of pro‑inflammatory neuropeptides, thereby reducing the transmission of pain signals within the trigeminovascular system. This dual action helps to abort migraine attacks and relieve associated symptoms.

The prescribed dose of Imigran is determined by a qualified healthcare professional based on the individual’s clinical condition, previous response to therapy, and any contraindications. The product is supplied as a 6 mg/0.5 mL solution for subcutaneous injection, and the prescriber decides the number of doses, timing, and whether a repeat dose may be administered after a specified interval.

The safety of sumatriptan in pregnancy and lactation has not been definitively established. Current labeling advises that Imigran should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternative treatment options and risk assessment with their obstetrician or neurologist.

To place an order, visit the product page for Imigran on the GNH India website (gnhindia.com) and submit an enquiry specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide; the sales team will request verification of trade or institutional credentials, then respond with pricing, availability, shipping details—including cold‑chain handling if needed—and required import documentation.

Imigran (sumatriptan) belongs to the triptan class, which is distinct from analgesics such as NSAIDs and from newer CGRP‑targeted therapies. Compared with oral triptans, the subcutaneous injection provides a faster onset of relief, often within 10–15 minutes, making it useful for severe or rapidly progressing attacks. However, it shares the same contraindications related to cardiovascular disease and requires prescription oversight.

Imigran should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the vials in their original packaging to protect them from moisture and direct light. Do not freeze the product, and avoid exposing it to excessive heat or humidity, as these conditions could affect the stability and potency of the injectable solution.

Imigran is supplied as a sterile solution for subcutaneous injection. The recommended route is a single injection into the outer thigh or abdomen using a suitable needle, as instructed by a healthcare professional. Patients should be trained on proper injection technique, site rotation, and disposal of sharps in accordance with local safety regulations.

The most serious risks include cardiovascular events such as chest discomfort, myocardial ischemia, or severe hypertension, especially in patients with underlying heart disease. Additionally, rare but potentially fatal serotonin syndrome can occur when sumatriptan is combined with other serotonergic agents. Anaphylactic reactions and severe allergic responses are also possible and require immediate medical attention.

Imigran is contraindicated in individuals with a history of coronary artery disease, uncontrolled hypertension, cerebrovascular disease, hemiplegic or basilar migraine, or known hypersensitivity to sumatriptan or any component of the formulation. Patients currently taking ergot derivatives, monoamine oxidase inhibitors, or other triptans should also avoid using Imigran unless directed by a physician.